docetaxel anhydrous has been researched along with Optic Nerve Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
| Naidu Sugnanam, KK; O'Hagan, S; Turner, NH | 1 |
2 other study(ies) available for docetaxel anhydrous and Optic Nerve Diseases
| Article | Year |
|---|---|
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma.
Topics: Adrenal Cortex Hormones; Docetaxel; Humans; Male; Middle Aged; Optic Nerve Diseases; Prostatic Neoplasms; Taxoids; Treatment Outcome; Visual Fields | 2017 |